Anupam Rasayan India Ltd Q4 FY2025 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/au4kczqejeftinng4yy72ide.pdf

Key Takeaways


Demand Environment & Segment Recovery

Anand Desai: "As business growth resumes, customers shall be able to reciprocate by supporting us in optimizing our working capital cycle going forward."

Revenue Growth & LOI Commercialization

Vishal Thakkar: "We should be coming back to our historical growth rates, which have been in the range of 25% to 30% plus. And I think we should be able to continue to see that kind of a growth from '26 onwards."

New Business Development

Vishal Thakkar: "With Elementium, we are the primary supplier for them for this product. And again, this is a product from Tanfac and the acquisition of Tanfac as well. So we believe that we have a very strong edge on this product."

Margins & Mix

Vishal Thakkar: "The margins will be quite similar if you really see... the current margins, which you look at, has also been in the similar range, and we expect that the newer products should also give us a similar kind of a margin range, 26% to 28%, which historically we've been guiding."

Balance Sheet & Working Capital


Guidance & Commitments

CommitmentSpecificsTimeline
Revenue growthReturn to historical growth rates of 25% to 30%+FY26 onwards
Japan revenue shareCross 20% of salesFY26
U.S. revenue shareBegin contributing meaningfully, cross 10% of salesFY26
LOI commercializationMajority of balance LOIs beyond the INR3,100 crores already doneFY26
EBITDA margin26% to 28% rangeFY26
Long-term debtReduced to practically zero via warrant conversionFY26
Working capital daysTarget of ~200 days (±20 days)FY27
Elementium commercializationFirst volumes for lithium-ion battery electrolytes2026

Key Metrics

MetricQ4 FY25
Consolidated revenue₹506 cr, +22% YoY and +31% QoQ
Full-year consolidated revenue₹1,448 cr, -4% YoY
Operating revenue (FY25)₹1,437 cr, -2.6% YoY
EBITDA (incl. other income)₹150 cr, +43% YoY; margin of 30%
Full-year EBITDA (incl. other income)₹412 cr, +0.4% YoY; margin of 29%
Profit after tax₹63 cr, +56% YoY
Full-year profit after tax₹160 cr, vs ₹167 cr in FY24
Pharma segment revenue growth+41% YoY in Q4; +92% YoY in FY25, reaching 21.9% of sales
Japan revenue contribution17% of sales, expected to exceed 20% in FY26
US revenue contribution expectationOver 10% of sales in FY26
Order book₹14,646 cr, spread over 4–10 years; ₹3,100 cr commercialized, contributing over 20% of FY25 revenue
Capex completed~₹670 cr as of March 31, 2025; two facilities commercialized, one ready for commercialization
Long-term debt to be settled via warrants~₹185 cr expected in FY26
Molecules launched in FY259 total: 5 in Pharma, 3 in agro, 1 in Polymer
Top 10 customer concentration71% of total revenue
Life science-related specialty chemicals share84.4% of Q4 revenue; 86.7% of FY25 revenue
Revenue growth guidance25% to 30%+ from FY26 onwards, returning to historical rates
EBITDA margin guidance26% to 28% for newer products
Net working capital days target200 days ±20 by FY27; 150–180 days for incremental revenue
Operating cash flow (H2 FY25)~₹140 cr
Short-term debt~₹1,100 cr